Salicylhydroxamic Acid

Identification

Name
Salicylhydroxamic Acid
Accession Number
DB03819  (EXPT02900)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
8Q07182D0T
CAS number
89-73-6
Weight
Average: 153.1354
Monoisotopic: 153.042593095
Chemical Formula
C7H7NO3
InChI Key
HBROZNQEVUILML-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO3/c9-6-4-2-1-3-5(6)7(10)8-11/h1-4,9,11H,(H,8,10)
IUPAC Name
N,2-dihydroxybenzamide
SMILES
ONC(=O)C1=CC=CC=C1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Salicylhydroxamic Acid.Approved, Investigational
AmrinoneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Amrinone.Approved
AranidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Aranidipine.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Barnidipine.Approved
BencyclaneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Bepridil.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Bioallethrin.Approved, Experimental
BuspironeThe metabolism of Buspirone can be decreased when combined with Salicylhydroxamic Acid.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Salicylhydroxamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Salicylhydroxamic Acid.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
DotarizineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Salicylhydroxamic Acid.Approved
FelodipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Fendiline.Withdrawn
Fish oilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlunarizineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of Salicylhydroxamic Acid can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Gallopamil.Investigational
IsradipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Salicylhydroxamic Acid.Approved
Magnesium sulfateThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Manidipine.Approved, Investigational
MentholThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Menthol.Approved
MethsuximideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Methsuximide.Approved
MibefradilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nitrendipine.Approved, Investigational
NylidrinThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nylidrin.Approved
OtiloniumThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Salicylhydroxamic Acid.Approved, Vet Approved
PinaveriumThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Salicylhydroxamic Acid.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Salicylhydroxamic Acid.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Salicylhydroxamic Acid.Approved, Investigational
SeletracetamThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Seletracetam.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Salicylhydroxamic Acid.Approved
SucralfateSucralfate can cause a decrease in the absorption of Salicylhydroxamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Salicylhydroxamic Acid.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Salicylhydroxamic Acid.Approved, Investigational
TerodilineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Tranilast.Approved, Investigational
TrimebutineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Trimethadione.Approved
VerapamilThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Salicylhydroxamic Acid.Approved
ZonisamideThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11343
PubChem Compound
66644
PubChem Substance
46507261
ChemSpider
60011
BindingDB
50015089
ChEBI
45615
ChEMBL
CHEMBL309339
Therapeutic Targets Database
DNC001266
HET
SHA
PDB Entries
1ck6 / 1v0h / 2qpk / 3fnl / 3gcj / 3vll

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility8.03 mg/mLALOGPS
logP0.21ALOGPS
logP1.17ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.01ChemAxon
pKa (Strongest Basic)-5.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area69.56 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity38.88 m3·mol-1ChemAxon
Polarizability14.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.8822
Caco-2 permeable-0.5208
P-glycoprotein substrateNon-substrate0.8589
P-glycoprotein inhibitor INon-inhibitor0.9334
P-glycoprotein inhibitor IINon-inhibitor0.9898
Renal organic cation transporterNon-inhibitor0.9412
CYP450 2C9 substrateNon-substrate0.8185
CYP450 2D6 substrateNon-substrate0.7869
CYP450 3A4 substrateNon-substrate0.6227
CYP450 1A2 substrateNon-inhibitor0.7641
CYP450 2C9 inhibitorNon-inhibitor0.9232
CYP450 2D6 inhibitorNon-inhibitor0.7257
CYP450 2C19 inhibitorNon-inhibitor0.9045
CYP450 3A4 inhibitorNon-inhibitor0.8834
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7763
BiodegradationNot ready biodegradable0.6014
Rat acute toxicity1.5175 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9866
hERG inhibition (predictor II)Non-inhibitor0.9257
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Hydroxamic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Salicylamide / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Hydroxamic acid / Carboxylic acid derivative / Organic nitrogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, hydroxamic acid (CHEBI:45615)

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 07:21